Hakutulokset - Daniel Oder

  • Näytetään 1 - 6 yhteensä 6 tuloksesta
Tarkenna hakua
  1. 1
    Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y

    Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y Tekijä Daniel Oder, Nurcan Üçeyler, Dan Liu, Kai Hu, Bernhard Petritsch, Claudia Sommer, Georg Ertl, Christoph Wanner, Peter Nordbeck

    Julkaistu 2016
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year

    Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year Tekijä Jonas Müntze, Daniel Gensler, Octavian Maniuc, Dan Liu, Tereza Cairns, Daniel Oder, Kai Hu, Kristina Lorenz, Stefan Frantz, Christoph Wanner, Peter Nordbeck

    Julkaistu 2018
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study

    Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study Tekijä Maarten Arends, Christoph Wanner, Derralynn Hughes, Atul Mehta, Daniel Oder, Oliver Watkinson, Perry Elliott, Gabor E. Linthorst, Frits A. Wijburg, Marieke Biegstraaten, Carla E. M. Hollak

    Julkaistu 2016
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors

    Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors Tekijä Maarten Arends, Marieke Biegstraaten, Derralynn Hughes, Atul Mehta, Perry Elliott, Daniel Oder, Oliver Watkinson, Frédéric M. Vaz, André B. P. Kuilenburg, Christoph Wanner, Carla E. M. Hollak

    Julkaistu 2017
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    Impact of immunosuppressive therapy on therapy‐neutralizing antibodies in transplanted patients with Fabry disease

    Impact of immunosuppressive therapy on therapy‐neutralizing antibodies in transplanted patients with Fabry disease Tekijä Malte Lenders, Daniel Oder, Albina Nowak, Sima Canaan‐Kühl, Laila Arash‐Kaps, Christiane Drechsler, Boris Schmitz, Peter Nordbeck, Julia B. Hennermann, Christoph Kampmann, Stefan Reuter, Stefan‐Martin Brand, Christoph Wanner, E. Brand

    Julkaistu 2017
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  6. 6
    Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study

    Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study Tekijä Maarten Arends, Marieke Biegstraaten, Christoph Wanner, Sandra Sirrs, Atul Mehta, Perry Elliott, Daniel Oder, Oliver Watkinson, Daniel G. Bichet, Anzalee Khan, Mark Iwanochko, Frédéric M. Vaz, André B. P. Kuilenburg, Michael L. West, Derralynn Hughes, Carla E. M. Hollak

    Julkaistu 2018
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: